Are you Dr. Abella?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1432 S Dobson Rd
Ste 107
Mesa, AZ 85202Phone+1 480-833-1123Fax+1 480-833-1124
Summary
- Dr. Esteban Abella, MD is a pediatric hematologist/oncologist in Mesa, Arizona. He is currently licensed to practice medicine in Arizona.
Education & Training
Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Universidad Central del Este Facultad de MedicinaClass of 1985
Certifications & Licensure
AZ State Medical License 2003 - 2025
Clinical Trials
- Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Start of enrollment: 1987 Aug 01
- Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Start of enrollment: 1998 Aug 01
Publications & Presentations
PubMed
- 64 citationsIdelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapyAjay K. Gopal, Brad S. Kahl, Christopher R. Flowers, Peter Martin, Stephen M. Ansell
Blood. 2017-06-01 - 119 citationsPhase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M. Barr, Gene Brian Saylors, Stephen E. Spurgeon, Bruce D. Cheson, Daniel Reif Greenwald
Blood. 2016-05-19 - 19 citationsAssessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Gary H. Lyman, David C. Dale, Jason C. Legg, Esteban Abella, Phuong Khanh Morrow
Cancer Medicine. 2015-08-01
Press Mentions
Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)June 3rd, 2019
